Clinical potential of angiogenic therapy and cellular reprogramming

Abstract

Feature Editor Note-You're driving along the freeway during rush hour. You're running late and find yourself in bumper-to-bumper traffic. You have 3 options: (1) do nothing, suffer with anguish inside; (2) find productive ways to pass the time, like listen to a podcast or talk on the phone; or (3) get off on the next exit and find an alternative, roundabout path to your destination. Similarly, patients suffering from coronary artery disease can opt to do nothing; stop progression and treat their symptoms with medical therapy; or undergo revascularization either percutaneously or surgically.There are few options, however, for those who develop chronic coronary artery disease without suitable revascularization strategies. They have missed their exit and are stuck in this metaphorical traffic jam, with no radio and no cell phone. These patients may experience refractory angina or develop ischemic cardiomyopathy and heart failure. Exploring solutions to this increasingly widespread problem is imperative. Chronic heart failure is rising, while the number of organs available for transplantation remains limited. Similarly, bridge therapies such as ventricular assist devices are resource intensive and are typically only performed at select, high-volume institutions.

LC-MS Analysis of Ginsenosides in Different Parts of Panax quinquefolius and Their Potential for Coronary Disease Improvement

“…Coronary artery disease (CAD) is among the cardiovascular disease entities and will soon be the leading cause of death globally. Therapeutic angiogenesis is a promising strategy for revolutionizing the treatment of CAD, and the components for stimulating the growth of new blood vessels in the heart are highlighted in current clinical trials 20 , 21 . Many proteins necessary for blood vessel growth in zebrafish are highly conserved and the same as those in mammals.…”

Bioengineering Human Tissues and the Future of Vascular Replacement

“…[96][97][98][99][100] Cardiac gene therapy that aims to reconstitute myocardium, as opposed to simply increasing angiogenesis, may help resolve some of the obstacles that myocardial cell therapy faces, including poor electromechanical integration and low implanted cell survival. 101…”

Upcoming expert opinions on adult coronary surgery

“…The authors suggest that this pathway of thrombosis may offer specific, targeted therapies to prevent graft occlusion; however, further investigation is needed before clinical implementation. 14 Looking forward, Ryan and colleagues 15 from Baylor College of Medicine will offer a thoughtful review of therapeutic angiogenesis and direct cellular reprogramming. The authors highlight how both can address the current gap in therapeutic options that exist for patients with no-option refractory angina and heart failure due to severe coronary artery disease.…”